Compugen stock maintained at Buy by H.C. Wainwright, $4 target
H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.
How this was made
The 30-second read
Why it matters
The analyst's reiteration of a Buy rating and a $4 target, combined with trial enrollment progress, creates a bullish catalyst for the stock.
Market read
The article provides fresh analyst coverage and trial enrollment data, offering a medium‑term upside thesis for CGEN.
What to watch
Potential delays in trial readout and reliance on partnership payments for cash flow.
Background
Compugen (NASDAQ:CGEN) is a clinical‑stage biotech focused on immune‑checkpoint therapies. The MAIA‑ovarian study evaluates COM701 in relapsed ovarian cancer.
Ticker impact
H.C. Wainwright reiterated a Buy rating with a $4 price target after Compugen's Q3 results and enrollment update for its MAIA-ovarian trial.
likely upward pressure as the market prices in the $4 target versus current $2.09 price
The buy rating and target provide a clear actionable catalyst; trial enrollment indicates future revenue upside.
Market effects
Positive signal for clinical‑stage biotech sector as trial progress may boost peer valuations.
Limited to US biotech investors.
Modest; primarily affects investors tracking small‑cap biotech stocks.
Counterpoint
The revenue miss and lack of EPS guidance could temper enthusiasm despite the upgrade.
Key entities
- companyCompugen
Clinical‑stage biotech developing COM701.
- analyst_firmH.C. Wainwright
Equity research firm issuing the Buy rating.



